CN106974954A - A kind of preparation method and purposes of oxtongue extract - Google Patents
A kind of preparation method and purposes of oxtongue extract Download PDFInfo
- Publication number
- CN106974954A CN106974954A CN201710127087.2A CN201710127087A CN106974954A CN 106974954 A CN106974954 A CN 106974954A CN 201710127087 A CN201710127087 A CN 201710127087A CN 106974954 A CN106974954 A CN 106974954A
- Authority
- CN
- China
- Prior art keywords
- extract
- oxtongue
- preparation
- water
- petroleum ether
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000284 extract Substances 0.000 title claims abstract description 54
- 235000017847 Anchusa officinalis Nutrition 0.000 title claims abstract description 49
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 241000734282 Helminthotheca echioides Species 0.000 title claims abstract 11
- 239000003814 drug Substances 0.000 claims abstract description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000011347 resin Substances 0.000 claims abstract description 11
- 229920005989 resin Polymers 0.000 claims abstract description 11
- 238000000605 extraction Methods 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 18
- 239000003208 petroleum Substances 0.000 claims description 15
- 238000010828 elution Methods 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- 239000012141 concentrate Substances 0.000 claims description 10
- 239000000287 crude extract Substances 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 10
- 238000010521 absorption reaction Methods 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 230000036541 health Effects 0.000 claims description 6
- 239000002250 absorbent Substances 0.000 claims description 5
- 230000002745 absorbent Effects 0.000 claims description 5
- 239000012895 dilution Substances 0.000 claims description 5
- 238000010790 dilution Methods 0.000 claims description 5
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000000047 product Substances 0.000 claims description 4
- 208000026139 Memory disease Diseases 0.000 abstract description 8
- 230000003446 memory effect Effects 0.000 abstract description 4
- 238000005516 engineering process Methods 0.000 abstract description 3
- 230000006872 improvement Effects 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 238000003908 quality control method Methods 0.000 abstract description 2
- 206010027175 memory impairment Diseases 0.000 abstract 1
- 238000001179 sorption measurement Methods 0.000 abstract 1
- 244000242323 Anchusa officinalis Species 0.000 description 38
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 8
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 7
- 230000002567 autonomic effect Effects 0.000 description 7
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 6
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 6
- 229960004373 acetylcholine Drugs 0.000 description 6
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 6
- 229960002646 scopolamine Drugs 0.000 description 6
- 206010012289 Dementia Diseases 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical group CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 238000012347 Morris Water Maze Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical group NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- -1 phenolic acid compound Chemical class 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000006386 memory function Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 235000002937 Clintonia borealis Nutrition 0.000 description 1
- 240000002814 Clintonia borealis Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 235000007602 Opuntia linguiformis Nutrition 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- JDXYSCUOABNLIR-UHFFFAOYSA-N diethyl 2-oxobutanedioate Chemical compound CCOC(=O)CC(=O)C(=O)OCC JDXYSCUOABNLIR-UHFFFAOYSA-N 0.000 description 1
- ADYPXRFPBQGGAH-WVVAGBSPSA-N dihydroergotoxine Chemical class CS(O)(=O)=O.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C=3C=CC=C4NC=C(C=34)C2)C1)C)C1=CC=CC=C1 ADYPXRFPBQGGAH-WVVAGBSPSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- JUMYIBMBTDDLNG-OJERSXHUSA-N hydron;methyl (2r)-2-phenyl-2-[(2r)-piperidin-2-yl]acetate;chloride Chemical compound Cl.C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 JUMYIBMBTDDLNG-OJERSXHUSA-N 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000007087 memory ability Effects 0.000 description 1
- 230000001343 mnemonic effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 229960004526 piracetam Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940099204 ritalin Drugs 0.000 description 1
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 description 1
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of oxtongue extract and preparation method thereof, and improved using the oxtongue extract or improve the new application of learning memory.It will be that Uygur medicine oxtongue is extracted through hydrous ethanol, the oxtongue extract obtained after extract and separate and macroporous adsorption resin technology processing.The oxtongue extract that the present invention is provided has increase significantly learning memory activity, the hypomnesia available for improvement learning memory disorder Disease.This preparation method is safe and simple, it is easy to quality control, is adapted to industrialized production.
Description
Technical field
The present invention relates to a kind of preparation method and purposes of oxtongue extract, the extract, which can be used for preparing, to be improved or changes
Application in kind learning memory medicine, belongs to technical field of Chinese medicine.
Background technology
Memory disorders（Memory Disorders）, the shape of information or technical ability can not be remembered or recall in a kind of by referring to individual
State, it is possible to be due to physiopathological or it is situational the reason for caused permanently or temporarily property memory disorders.Study
Memory disorders refer to that a kind of pathological state of learning and memory ability decline occurs under certain inducement in body, according to its inducement not
It is same to be classified as two classes.One class belongs to Aging learning memory disorder, and main inducing causes for the decline of organ or function
Learning and memory function decline, common are aging, climacteric, senile dementia, cerebral blood supply insufficiency etc.；It is another kind of to belong to tired
Tired inquiry learning memory disorders, the decline for the learning and memory function of being caused mainly due to long-term or slow stress, often
Inferior health is seemed, confirmed fatigue is long-term overstrain one's nerves etc..Scientific research is proved in recent years, and free radical has with memory disorders
Closely related, internal polyradical of crossing is accumulated in brain cell, can cause failure of memory or dysnoesia, or even occur old
It is dull-witted.Central cholinergic system is with learning, remembering closely related, acetylcholine（Acetylcholine, Ach）It is maincenter choline
One of important neurotransmitter in energy system, wherein major function are to maintain regaining consciousness for consciousness, are played in learning and memory important
Effect.And acetylcholinesterase（Acetylcholine esterase, AchE）ACh can be made to be hydrolyzed into choline and acetic acid, caused
Maincenter ACh is lacked, and ACh missings cause cognitive function to be lost, memory capability decline.But effective method treatment memory is there is no at present
Obstacle, mainly finds out protopathy, is treated for protopathy, fat foods containing lecithin, the precursor of neurotransmitter, ritalin,
The curative effects such as the expansion blood vessel medicine of dihydroergotoxine class hardly possible is fixed.
Oxtongue is the Italian oxtongue of comfreyAnchusa italice Retz.Or Common BorageBorage officinales L. aerial part.Summer spends peak period, typically extracts aerial part and dries.The micro- fragrance of gas, lightly seasoned, tool is viscous
Property, it is one of medicinal herbs most in use of Uygur medicine treatment cardiovascular and cerebrovascular disease, dimension medicine name Gao Ziwan.Such a medicinal material is more by Pakistan
Import, a large amount of artificial cultivations in present Xinjiang South Sinkiang Kaxgar Prefecture.Oxtongue has raw humidogene heat, and the black courage matter of dysregulation, life is wet
Cerebrum tonifying, dispelling cold bushing, the heart of feeling well pleases will, anti-inflammatory is moisturized, the effects such as relieving cough and asthma.Dry cold or black courage matter disease is cured mainly, it is such as flat
Property brain it is empty, it is cold have a guilty conscience, palpitaition, depression, dryness meningitis, pneumonia and tuberculosis disease, cold cough, flu, asthma etc..Entirely
Grass has soap former times, flavonoids, amino acid, volatile oil, vigorous liquid matter, carbohydrate and Alkaloid reaction through prerun.
The plant of oxtongue category is among the people for controlling treatment trauma, gastric ulcer and urinary tract infections etc. in Turkey, India and Jordan
Illness.The scholar of Turkey（Helvetica Chimica Acta,93:457,2010 ）The chemical composition of oxtongue is have studied,
Therefrom separation identifies 11 chemical compositions, predominantly triterpenoid saponin, flavonoids, aliphatic acid and phenolic acid compound, and sends out
Its existing extracting n-butyl alcohol position and a flavone compound quercetin3-（a-rhamnopyranosyl-β-
glucopyranoside）With a phenolic acid compound rosmarinic acid have very strong anti-DPPH (2,2-
Diphenyl-l- picrylhydrazyl) free radical effect.Publication No. CN103463163 A Chinese invention patent
Document discloses a kind of Italian oxtongue active site answering in antioxidation medicine, cosmetics and health products
With Italian cow tongue ethyl oxalacetate and n-butanol portion have good antioxidation.
Comprehensive existing literature data, does not find that oxtongue and its extract or its ingredient improve or improved learning and memory
The document and patent report of power activity.
The content of the invention
It is an object of the invention to provide a kind of preparation method and purposes of oxtongue extract, carried with the oxtongue of preparation
Take thing to be processed into raising or improve learning memory medicine and health products, learning memory activity can be significantly improved, improve or
Improve learning memory.
A kind of preparation method for oxtongue extract that the present invention is provided, comprises the following steps：
（1）, take dry, crush oxtongue, add mass ratio be 1:10~15 75% ethanol, soaks 8h, reheats backflow
Extract 2~4 times, each extraction time is 2~3 hours, merges extract solution, and vacuum is filtered, and removes insoluble substance, filtrate is through subtracting
Pressure is concentrated into extract solution without alcohol taste, obtains concentrating crude extract；
（2）, the crude extract that obtains step 1 and petroleum ether volume ratio be 1:3~5 mixing carry out repeatedly extraction and two-phase laminated flow,
Until petroleum ether layer is colourless, petroleum ether layer is discarded, combining water layer is concentrated under reduced pressure, it is standby during to 0.25~1.0 g crude drugs/mL.
（3）Concentrate in step 2 is added into 3 times of amount water dilutions, stood after 12 h, vacuum is filtered, and removes insoluble substance, filter
Liquid it is concentrated to 0.25~1.0 g crude drugs/mL when it is standby；
（4）, by the concentrate in step 3 and AB-8 macroporous absorbent resins with 1:5~10 weight are than implementing to adsorb, and resin column footpath is high
Than for 1:1~1:6, applied sample amount is 0.1 mg/mL/ milliliters of column volume, is first eluted with water colourless to efflux after absorption, will be washed
After de- liquid is discarded, then eluted for 70% ethanol water with volume fraction, elution volume is 3 times of column volumes, and elution flow is
1mL/min;Obtained eluate is concentrated under reduced pressure, and is then dried in vacuo, and produces described oxtongue extract.
A kind of purposes of oxtongue extract, described oxtongue extract and one or more pharmaceutically acceptable loads
Body or excipient are mixed in proportion, and the pharmaceutical composition of the different dosage forms suitable for clinically using is made, adds further according to needs
Enter the tax such as appropriate diluent, dispersant, wetting agent, adhesive, disintegrant, lubricant, solubilizer, antioxidant, flavouring
Shape agent, is made the formulation being properly administered.
Show that primary efficacy of the present invention is acted on by the result of zoopery as follows：
The time that mouse finds platform in water maze can substantially be shortened, increase mouse passes through the number of times of platform, mouse study note
Recall power to significantly improve;
Mouse can substantially be shortened to stand in autonomic activities instrument and movable number of times, it was demonstrated that the mouse after gavage oxtongue extract
Mnemonic learning ability is significantly improved;
The positive effect of the present invention is：The extract of the present invention is prepared from by single dimension medicinal material extract, with significantly carrying
High or improvement learning memory activity, and it is easy to quality control compared to the Chinese patent drug of multi-flavor medicine prescription, while preparation technology is simple
It is single, it is adapted to industrialized production.
Embodiment
Embodiment 1：
The preparation method of oxtongue extract comprises the following steps：
The oxtongue dried, crushed is taken, it is 1 to add mass ratio:10 75% ethanol, soaks 8h, reheats refluxing extraction 3 times,
Each extraction time is 2 hours, merges extract solution, and vacuum is filtered, and removes insoluble substance, filtrate is through being concentrated under reduced pressure into extract solution
Without alcohol taste, obtain concentrating crude extract.The crude extract that step 1 is obtained is 1 with petroleum ether volume ratio:3 mixing are repeatedly extracted
With two-phase laminated flow, until petroleum ether layer is colourless, petroleum ether layer is discarded, combining water layer is concentrated under reduced pressure, it is standby during to 0.5 g crude drugs/mL
With.Concentrate in step 2 is added into 3 times of amount water dilutions, stood after 12 h, vacuum is filtered, and removes insoluble substance, concentrating filter liquor
It is standby during to 0.5 g crude drugs/mL；By the concentrate in step 3 and AB-8 macroporous absorbent resins with 1:5 weight are adsorbed than implementation,
Resin column blade diameter length ratio is 1:4, applied sample amount is 0.1 mg/mL/ milliliters of column volume, be first eluted with water after absorption it is colourless to efflux,
After water elution is discarded, then eluted for 70% ethanol water with volume fraction, elution volume is 3 times of column volumes, elution stream
Amount is 1mL/min;Obtained eluate is concentrated under reduced pressure, and is then dried in vacuo, and produces described oxtongue extract.
Embodiment 2：
The preparation method of oxtongue extract comprises the following steps：
The oxtongue dried, crushed is taken, it is 1 to add mass ratio:The ethanol that 12 times of volume fractions are 75%, soaks 8h, reheats back
Stream is extracted 3 times, and each extraction time is 2 hours, merges extract solution, and vacuum is filtered, and removes insoluble substance, and filtrate is dense through depressurizing
Extract solution is reduced to without alcohol taste, obtains concentrating crude extract.The crude extract that step 1 is obtained is 1 with petroleum ether volume ratio:4 are mixed into
Row is repeatedly extracted and two-phase laminated flow, until petroleum ether layer is colourless, petroleum ether layer is discarded, combining water layer is concentrated under reduced pressure, to 0.5 g
It is standby during crude drug/mL.Concentrate in step 2 is added into 3 times of amount water dilutions, stood after 12 h, vacuum is filtered, and removes insoluble thing
Matter, it is standby when concentrating filter liquor is to 1.0 g crude drugs/mL；By the concentrate in step 3 and AB-8 macroporous absorbent resins with 1:6 weights
Amount is 1 than implementing absorption, resin column blade diameter length ratio:5, applied sample amount is 0.1 mg/mL/ milliliters of column volume, is first eluted with water after absorption
It is colourless to efflux, after water elution is discarded, then with volume fraction for 70% ethanol water elute, elution volume be 3 times
Column volume, elution flow is 1mL/min;Obtained eluate is concentrated under reduced pressure, and is then dried in vacuo, and produces described ox
Diffusa extract.
Embodiment 3：
The preparation method of oxtongue extract comprises the following steps：
The oxtongue dried, crushed is taken, it is 1 to add mass ratio:15 75% ethanol, soaks 8h, reheats refluxing extraction 2 times,
Each extraction time is 2 hours, merges extract solution, and vacuum is filtered, and removes insoluble substance, filtrate is through being concentrated under reduced pressure into extract solution
Without alcohol taste, obtain concentrating crude extract.The crude extract that step 1 is obtained is 1 with petroleum ether volume ratio:5 mixing are repeatedly extracted
With two-phase laminated flow, until petroleum ether layer is colourless, petroleum ether layer is discarded, combining water layer is concentrated under reduced pressure, it is standby during to 1.0 g crude drugs/mL
With.Concentrate in step 2 is added into 3 times of amount water dilutions, stood after 12 h, vacuum is filtered, and removes insoluble substance, concentrating filter liquor
It is standby during to 1.0 g crude drugs/mL；By the concentrate in step 3 and AB-8 macroporous absorbent resins with 1:4 weight are adsorbed than implementation,
Resin column blade diameter length ratio is 1:6, applied sample amount is 0.1 mg/mL/ milliliters of column volume, be first eluted with water after absorption it is colourless to efflux,
After water elution is discarded, then eluted for 70% ethanol water with volume fraction, elution volume is 3 times of column volumes, elution stream
Amount is 1mL/min;Obtained eluate is concentrated under reduced pressure, and is then dried in vacuo, and produces described oxtongue extract.
The inventive method obtains the Behaviors survey checking of oxtongue extract, has the learning memory work that increases significantly
Property.
1）Mouse Morris water maze laboratories
From body weight (18-22g), Kunming male mice is divided into 5 groups, respectively every group 10, Normal group, hyoscine mould
Type group, oxtongue extract high dose group（6.0g/kg）, middle dose group（4.0g/kg,）And low dose group（2.0g/kg）, brain it is multiple
Health (100mg/kg) positive controls.Continuously gavage the modeling after seven days of each test medicine, Normal group and hyoscine model
Group gavages etc. dosage physiological saline daily.In addition to the dosage physiological saline such as Normal group intraperitoneal injection, remaining 4 groups of mouse peritoneal
Injection hyoscine (1mg/1kg) sets up Model of Dementia, gives progress Morris water maze laboratories after hyoscine 30minn.
Continuous 5 days of Morris water maze tests, are divided into orientation navigation experiment and space exploration experiment, are within first 4 days that orientation navigation is tested.It is flat
Platform is located at Southwest Quadrant center, and mouse enters water from Northeast Quadrant and Northwest Quadrant daily, and record finds plateau time.As do not found
Platform incubation period is recorded as 120s.Carry out space exploration experiment within 5th day, remove platform, mouse enters water from selected quadrant, records small
Mouse spanning platform number of times.
Morris water maze laboratory results show that it is notable that model group mouse finds platform incubation period in orientation navigation experiment
Higher than Normal group, the success of dementia mice model copy caused by pointing out hyoscine.Compared with model group, oxtongue extract
Low, high dose group and piracetam group can shorten dementia mice and find platform incubation period, wherein oxtongue extract high dose group
There is significant difference with piracetam group（P<0.05）.In space exploration experiment, compared with model group mouse, oxtongue extract
High and low dose group can increase spanning platform number of times, but not up to significant difference to a certain extent.Piracetam group can significantly increase
Plus dementia mice spanning platform number of times（P<0.05）, the dementia mice study note for pointing out oxtongue extract to induce hyoscine
Recall damage to have some improvement, be shown in Table 1,2.
2）Mouse autonomic activities is tested
From body weight (18-22g), kunming mice is divided into 4 groups, and every group 10, respectively Normal group, oxtongue extract is high
Dosage group（6.0g/kg）, middle dose group（4.0g/kg,）And low dose group（2.0g/kg）, and blank control group test mice is passed through
Mouse is placed in autonomic activities case, instrument by the isometric physiological saline of mouthful gavage, all gastric infusion daily, continuous gavage after 7 days
The autonomic activities that device records mouse in 5min automatically is stood and movable number of times.
Autonomic activities experimental result shows that the high, medium and low dosage group mouse of oxtongue extract is in autonomic activities instrument
Number of activities and standing number of times have the difference of conspicuousness compared with blank group（P<0.05）, this illustrates that oxtongue extract can change
Kind mouse activity and the number of times stood, make mouse more be familiar with and remember the dark environment of autonomic activities instrument having no danger,
Illustrate that oxtongue extract has the effect for improving memory, be shown in Table 3.
Verified by above-mentioned Behaviors survey, oxtongue extract has the learning memory activity that increases significantly, and shows
Oxtongue extract, which has, improves or improves the purposes of learning memory medicine.Described oxtongue extract, which is used to prepare, to be improved
Or improve the medicine and health products of learning memory.
Claims (2)
1. a kind of preparation method of oxtongue extract, it is characterised in that the preparation method comprises the following steps：
（1）, take dry, crush oxtongue, add mass ratio be 1:10~15 75% ethanol, soaks 8h, reheats backflow
Extract 2~4 times, each extraction time is 2~3 hours, merges extract solution, and vacuum is filtered, and removes insoluble substance, filtrate is through subtracting
Pressure is concentrated into extract solution without alcohol taste, obtains concentrating crude extract；
（2）, the crude extract that obtains step 1 and petroleum ether volume ratio be 1:3~5 mixing carry out repeatedly extraction and two-phase laminated flow,
Until petroleum ether layer is colourless, petroleum ether layer is discarded, combining water layer is concentrated under reduced pressure, it is standby during to 0.25~1.0 g crude drugs/mL；
（3）Concentrate in step 2 is added into 3 times of amount water dilutions, stood after 12 h, vacuum is filtered, and removes insoluble substance, filtrate warp
It is concentrated into standby during 0.25~1.0 g crude drugs/mL；
（4）, by the concentrate in step 3 and AB-8 macroporous absorbent resins with 1:5~10 weight are than implementing to adsorb, and resin column footpath is high
Than for 1:1~1:6, applied sample amount is 0.1 mg/mL/ milliliters of column volume, is first eluted with water colourless to efflux after absorption, will be washed
After de- liquid is discarded, then eluted for 70% ethanol water with volume fraction, elution volume is 3 times of column volumes, and elution flow is
1mL/min;Obtained eluate is concentrated under reduced pressure, and is then dried in vacuo, and produces described oxtongue extract.
2. a kind of purposes of oxtongue extract, it is characterised in that described oxtongue extract, which is used to prepare to improve or improve, to be learned
Practise the medicine and health products of memory.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2016111164752 | 2016-12-07 | ||
| CN201611116475 | 2016-12-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106974954A true CN106974954A (en) | 2017-07-25 |
Family
ID=59338693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710127087.2A Pending CN106974954A (en) | 2016-12-07 | 2017-03-06 | A kind of preparation method and purposes of oxtongue extract |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106974954A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101584752A (en) * | 2009-07-09 | 2009-11-25 | 山东轻工业学院 | Extraction and purification process for total flavonoids in Anchusa italica Retiz |
-
2017
- 2017-03-06 CN CN201710127087.2A patent/CN106974954A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101584752A (en) * | 2009-07-09 | 2009-11-25 | 山东轻工业学院 | Extraction and purification process for total flavonoids in Anchusa italica Retiz |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11517604B2 (en) | Method for preparing Plectranthus amboinicus fraction having anti-arthritis activity | |
| CN103816296B (en) | Callicarpa total glycoside extract and preparation method and application thereof | |
| CN101181317B (en) | Purslane extract as well as preparation method and application thereof | |
| CN1977951B (en) | Gastrodia elata plant extract for preventing senile dementia and its preparing method | |
| CN102247420B (en) | Preparation method and application of eclipta extract | |
| JP2006111560A (en) | Ceramide synthesis promoter | |
| Dua et al. | Role of traditional medicine in neuropsychopharmacology | |
| CN114432174B (en) | Use of Baimaigen seed extract and rhamnosyluridine | |
| KR20080064337A (en) | A.tuberosum rottl. extract having an activity of activating choline acetyltransferase in brain nerve cells | |
| CN102718817A (en) | Method for preparing anthocyanin extract from black bean peel | |
| US20190000905A1 (en) | Gynostemma pentaphyllum fermented extracts comprising Saponins as an active functional food ingredient and preparation method thereof | |
| KR101794006B1 (en) | Anti inflammatory comprising plant extract | |
| CN103721148B (en) | A kind of Fructus Alpiniae Oxyphyllae compositions treating acute/chronic gastroenteritis and preparation method thereof | |
| CN102895438B (en) | Application of rhizoma acori graminei extract in preparing drug for treating Alzheimer | |
| CN106974954A (en) | A kind of preparation method and purposes of oxtongue extract | |
| CN105796961A (en) | Application of dried tangerine peel and lalang grass rhizome composition in preparation of drug resisting vomiting due to chemotherapy | |
| CN105669378B (en) | Herba Euphorbiae Helioscopiae extract and preparation method and its usage | |
| WO2012146169A1 (en) | Chinese herbal extract, preparing method and application thereof | |
| CN104547148A (en) | Hedyotis diffusa extract used for preventing and treating senile dementia and preparation method of hedyotis diffusa extract | |
| JP4105498B2 (en) | A composition effective for prevention and alleviation of symptoms of atopic disease | |
| CN109846777A (en) | It is a kind of to have effects that alleviate composition of plant extracts of baby child's eczema and preparation method thereof, application | |
| CN109223739A (en) | A kind of composition and its preparation method and application | |
| CN102895439B (en) | Rhizoma acori graminei extract for treating Alzheimer and method for extracting rhizoma acori graminei extract for treating Alzheimer | |
| CN108619179A (en) | Geranium extract and its medical usage | |
| CN110123859B (en) | Chrysanthemum leaf extract for preventing and treating liver injury and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170725 |